Immunic (NASDAQ:IMUX) Raised to Strong-Buy at Zacks Research

by · The Markets Daily

Immunic (NASDAQ:IMUX – Get Free Report) was upgraded by stock analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research note issued to investors on Wednesday, Zacks reports.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a report on Wednesday, August 26th. Wall Street Zen lowered shares of Immunic from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Roth Capital reissued a “buy” rating on shares of Immunic in a research report on Tuesday, September 1st. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Finally, HC Wainwright reissued a “buy” rating and issued a $22.00 price target on shares of Immunic in a report on Thursday, September 10th. Four research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Immunic presently has a consensus rating of “Buy” and an average price target of $35.43.

Get Our Latest Research Report on IMUX

Immunic Trading Down 3.5%

Shares of NASDAQ:IMUX opened at $7.22 on Wednesday. The company has a 50 day moving average of $11.23 and a 200 day moving average of $12.52. The stock has a market cap of $98.48 million, a P/E ratio of -1.65 and a beta of 1.45. Immunic has a 12 month low of $5.06 and a 12 month high of $17.43.

Immunic (NASDAQ:IMUX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.36. On average, equities analysts forecast that Immunic will post -3.71 earnings per share for the current fiscal year.

Institutional Trading of Immunic

A number of hedge funds have recently made changes to their positions in IMUX. CTC Alternative Strategies Ltd. purchased a new stake in Immunic during the 1st quarter valued at about $27,000. ADAR1 Capital Management LLC bought a new stake in Immunic during the 1st quarter valued at about $33,000. Bank of America Corp DE raised its holdings in Immunic by 80,724.2% in the first quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock worth $160,000 after buying an additional 143,689 shares during the last quarter. OMERS ADMINISTRATION Corp purchased a new position in Immunic in the first quarter worth about $187,000. Finally, Simplify Asset Management Inc. purchased a new position in Immunic in the first quarter worth about $487,000. 51.82% of the stock is owned by institutional investors.

Immunic Company Profile

(Get Free Report)

Immunic, Inc is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract.

Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease.

See Also